Metabolic Syndrome Risk Factor in IGT: STOP-NIDDM Trial

NCT00629213 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1429

Enrollment

OTHER

Sponsor class

Conditions

Metabolic Syndrome

Interventions

DRUG: acarbose
DRUG: placebo

Sponsor

GWT-TUD GmbH